-
Notable Call Options Activity in BioMimetic Therapeutics
Friday, August 26, 2011 - 2:18pm | 92Shares of BioMimetic Therapeutics (NASDAQ: BMTI) are higher on the session by 6.60%, currently trading at $3.07. The stock has been moving largely lower over the past three months and is currently trading below the 50-day moving average. Options traders are focusing on calls today. A short while...
-
Notable Call Options Activity in Synovus Financial
Friday, August 26, 2011 - 11:54am | 89Shares of Synovus Financial (NYSE: SNY) are higher on the session by 0.77%, currently trading at $1.31. The stock has been moving largely lower over the past three months and is currently trading below the 50-day moving average. Options traders are focusing on calls today. A short while ago the...
-
Groupon's Andrew Mason: "I've Never Been More Confident and Excited about the Future of our Business"
Friday, August 26, 2011 - 9:54am | 1085In an internal memo sent to thousands of employees, Groupon CEO and co-founder Andrew Mason breaks his silence. Kara Swisher of AllThingsD has scored an exclusive look at the memo, which addresses the silly (if not absurd) controversy surrounding Groupon's accounting practices. Known as ACSOI (...
-
Piper Jaffray Reiterates Overweight on Watson Pharmaceuticals
Friday, August 26, 2011 - 6:18am | 74Piper Jaffray is out with its report today on Watson Pharmaceuticals (NYSE: WPI), reiterating Overweight. In its report, Piper Jaffray writes, "With strong visibility on double-digit EPS growth through at least 2013 and a P/E of only 10.5x our 2012 EPS estimate of $6.09, we believe WPI shares are...
-
12 Most Popular Healthcare Stocks Among Hedge Funds
Thursday, August 25, 2011 - 4:10pm | 975Insider Monkey follows hedge fund managers because they're the smartest investors around. They leave less to chance than do most investors. They go to great lengths to get an “edge” over ordinary investors. Hedge fund managers also have the resources to do extensive research on public companies and...
-
Eli Lilly Announces Linagliptin Receives Approval in Europe for the Treatment of Type 2 Diabetes
Thursday, August 25, 2011 - 1:50pm | 94Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today received Marketing Authorization from the European Commission for linagliptin 5 mg film-coated tablets (to be marketed under the trade name Trajenta® in Europe) for the treatment of adults with type 2 diabetes. The European...
-
UPDATE: FDA Approves Shire's FIRAZYR (icatibant injection) for Acute Attacks of Hereditary Angioedema
Thursday, August 25, 2011 - 10:19am | 217Shire (NASDAQ: SHPGY) today announced that the U.S. Food and Drug Administration has granted marketing approval for FIRAZYR® (icatibant injection) for treatment of acute attacks of hereditary angioedema in adults 18 years of age and older. "Until now, HAE patients faced challenges gaining rapid...
-
Hi-Tech Pharmacal Acquires Rights to TussiCaps Extended-Release Capsules to Be Promoted by Their ECR Pharmaceuticals Subsidiary
Thursday, August 25, 2011 - 7:04am | 204Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today announced it has acquired the marketing and distribution rights for TussiCaps® (hydrocodone polistirex and chlorpheniramine polistirex) extended-release capsules from Mallinckrodt LLC. The product is indicated for the treatment of cough and upper...
-
Simcere's Iremod Receives SFDA New Drug Approval
Thursday, August 25, 2011 - 7:02am | 90Simcere Pharmaceutical Group (NYSE: SCR) today announced that it has received the new drug approval from the State Food and Drug Administration ("SFDA") for Iremod. Iremod, which was independently developed by Simcere, will be the first Iguratimod drug on the global market. It is a new drug in the...
-
Hi-Tech Licenses Rights to Extended Release Antihistamine/Decongestant for its ECR Pharmaceuticals Subsidiary
Thursday, August 25, 2011 - 6:58am | 119Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced today that they acquired marketing and distribution rights to an ANDA filing from KVK-Tech, Inc. for dexbrompheniramine maleate 6mg/pseudoephedrine sulfate 120 mg extended release tablets. The product will be marketed by ECR, Hi-Tech's branded...
-
Hi-Tech Licenses Rights to Extended Release Antihistamine/Decongestant for its ECR Pharmaceuticals Subsidiary
Thursday, August 25, 2011 - 6:58am | 119Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced today that they acquired marketing and distribution rights to an ANDA filing from KVK-Tech, Inc. for dexbrompheniramine maleate 6mg/pseudoephedrine sulfate 120 mg extended release tablets. The product will be marketed by ECR, Hi-Tech's branded...
-
Piper Jaffray Reviews Allergan After FDA Action
Thursday, August 25, 2011 - 5:58am | 108Piper Jaffray has published a research report on Allergan Inc (NYSE: AGN) in light of recent FDA approval. In the report, Piper Jaffray wrote, "Yesterday, the FDA approved Botox for the treatment of neurogenic overactive bladder (nOAB) in patients who do not respond adequately to or cannot...
-
Notable Call Options Activity in Warner Chilcott
Wednesday, August 24, 2011 - 10:31am | 91Shares of Warner Chilcott (NASDAQ: WCRX) are lower on the session by 0.67%, currently trading at $16.28. The stock has been moving largely lower over the past three months and is currently trading below the 50-day average. Options traders are focusing on calls today. A short while ago the...
-
Morning Gainers; Bank of America up Over 8%
Wednesday, August 24, 2011 - 9:25am | 123Sodastream International (NASDAQ: SODA) +5.42% on heavy volume. MGM Resorts International (NYSE: MGM) +7.46% after touching 52-week lows yesterday. Bank of America Corp (NYSE: BAC) +8.57% after Raymond James reiterates Strong Buy and $16 PT. ATP Oil & Gas Corporation (NASDAQ: ATPG) +6.45 on...
-
Market Update
Wednesday, August 24, 2011 - 8:35am | 131Shares of JAKKS Pacific Inc (NASDAQ: JAKK) rose about 0.06% after the company appointed Jack McGrath as its Chief Operating Officer. Shares of Triangle Capital Corporation (NYSE: TCAP) dropped about 7.7% after the company priced a public offering of 3,500,000 shares of common stock at $17.15 per...